Latest From Aetna Inc.
Driven by increasingly cost-conscious payers, health care is shifting from a volume-based model to “value-based care,” now the latest buzzword. In response, the medical device industry has started employing new commercial strategies.
Express Scripts points to a relatively untapped market of 30m uninsured individuals who could be reached through a collaboration with Amazon if the e-commerce giant ventures into Rx drug sales.
US FDA's accelerated approval pathway is more reliable and has better validated biomarkers than a decade ago, commissioner says, arguing coverage limits on AA products are not in the interest of public health.
Manufacturing, distribution and pricing challenges for cell and gene therapies have been mostly hypothetical – until now. But with no industry standards, the first products to win approval are dictating the complex path forward.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Aetna Inc.
- Senior Management
Mark W Bertolini, Chmn. & CEO
Shawn M Guertin, EVP, CFO & Chief Enterprise Risk Officer
Harold L Paz, MD, EVP & CMO
- Contact Info
Phone: (860) 273-0123
151 Farmington Ave.
Hartford, CT 06156
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.